非小細胞肺がん市場- 世界の産業規模、動向、機会、および予測、2018年～2028年、タイプ別、薬剤クラス別、治療別、エンドユーザー別、地域別、競合

世界の非小細胞肺がん市場は、2022年に150億9,000万米ドルと評価され、2028年までのCAGRは9.60%で、予測期間中に力強い成長を予測しています。

世界の非小細胞肺がん（NSCLC）市場は、より広範なヘルスケアおよび製薬業界において、ダイナミックかつ重要なセグメントです。NSCLCは最も一般的な肺がんであり、全世界の肺がん患者の約85%を占める。この市場には、この生命を脅かす疾患と闘うことを目的とした、診断、治療、支持療法の幅広いソリューションが含まれています。

NSCLC市場の主要促進要因の一つは、主に喫煙、環境要因、世界人口の高齢化に起因する肺がん罹患率の上昇です。早期発見と正確な診断が近年非常に重要視されるようになり、市場の診断セグメントの大幅な成長につながっています。CTスキャンやPETスキャンのような高度な画像診断技術は、遺伝子検査やリキッドバイオプシーとともに、診断の精度を著しく向上させています。

NSCLCの治療状況は、標的療法や免疫療法の登場により著しい変貌を遂げています。EGFR阻害剤やALK阻害剤のような標的療法は、NSCLC患者の特定の遺伝子変異の管理に革命をもたらし、個別化治療の選択肢を提供しています。さらに、PD-1阻害剤やPD-L1阻害剤などの免疫チェックポイント阻害剤が有望な手段として登場し、がん細胞と闘う免疫系の能力を強化しています。

このような進歩にもかかわらず、NSCLC市場は、高額な治療費、特定の地域における革新的治療へのアクセスの制限、標的治療に対する耐性の出現などの課題に直面しています。さらに、これらの課題に対処し、患者の予後を改善するために、新規治療薬や併用療法を開発するための研究開発が進められています。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 非小細胞肺がんの世界市場展望

• 市場規模および予測
  • 金額別
• 市場シェアと予測
  • タイプ別（扁平上皮がん、大細胞がん、腺がん、その他）
  • 薬剤クラス別（上皮成長因子受容体（EGFR）阻害薬、未分化リンパ腫キナーゼ（ALK）阻害薬、ROS1阻害薬、BRAF阻害薬、その他）
  • 治療別（化学療法、標的療法、免疫療法）
  • エンドユーザー別（病院・クリニック、外来診療センター、その他）
  • 地域別
  • 企業別（2022年）
• 市場マップ
  • タイプ別
  • 薬剤クラス別
  • 治療別
  • エンドユーザー別
  • 地域別

第5章 アジア太平洋地域の非小細胞肺がん市場展望

• 市場規模および予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 薬剤クラス別
  • 治療別
  • エンドユーザー別
  • 国別
• アジア太平洋地域国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の非小細胞肺がん市場展望

• 市場規模および予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 薬剤クラス別
  • 治療別
  • エンドユーザー別
  • 国別
• 欧州国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の非小細胞肺がん市場展望

• 市場規模および予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 薬剤クラス別
  • 治療別
  • エンドユーザー別
  • 国別
• 北米国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の非小細胞肺がん市場展望

• 市場規模および予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 薬剤クラス別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの非小細胞肺がん市場展望

• 市場規模および予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 薬剤タイプ別
  • 治療別
  • エンドユーザー別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Eli Lilly and Company
  • Business Overview
  • Company Snapshot
  • Products & Services
  • Current Capacity Analysis
  • Financials（In case of listed）
  • Recent Developments
  • SWOT Analysis
• Sanofi SA
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Merck & Co., Inc.
• Pfizer Inc.
• AstraZeneca Plc
• Boehringer Ingelheim Inc.
• Bristol-Myers Squibb Company
• Astellas Pharma

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Non-Small-Cell Lung Cancer Market has valued at USD 15.09 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 9.60% through 2028. The Global Non-Small-Cell Lung Cancer (NSCLC) Market represents a dynamic and critical segment within the broader healthcare and pharmaceutical industry. NSCLC is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases worldwide. This market encompasses a wide array of diagnostic, therapeutic, and supportive care solutions aimed at combating this life-threatening disease.

One of the key drivers of the NSCLC market is the rising incidence of lung cancer, primarily attributed to smoking, environmental factors, and an aging global population. Early detection and accurate diagnosis have gained immense importance in recent years, leading to substantial growth in the diagnostic segment of the market. Advanced imaging techniques, such as CT scans and PET scans, along with genetic testing and liquid biopsies, have significantly improved the precision of diagnosis.

The treatment landscape of NSCLC has undergone a remarkable transformation with the advent of targeted therapies and immunotherapies. Targeted therapies, like EGFR and ALK inhibitors, have revolutionized the management of specific genetic mutations in NSCLC patients, offering personalized treatment options. Additionally, immune checkpoint inhibitors, such as PD-1 and PD-L1 inhibitors, have emerged as a promising avenue, bolstering the immune system's ability to combat cancer cells.

Despite these advancements, the NSCLC market faces challenges such as high treatment costs, limited access to innovative therapies in certain regions, and the emergence of resistance to targeted therapies. Furthermore, ongoing research and development efforts are focused on developing novel therapies and combination treatments to address these challenges and improve patient outcomes.

Key Market Drivers

Rising Incidence and Prevalence of Non-Small-Cell Lung Cancer (NSCLC)

The Global Non-Small-Cell Lung Cancer (NSCLC) Market is witnessing a significant boost due to the rising incidence and prevalence of this devastating disease. NSCLC has become increasingly prevalent on a global scale, primarily driven by several key factors. First and foremost is the persistent and widespread habit of smoking, which remains the leading cause of lung cancer. Despite public health campaigns and efforts to curb tobacco use, many individuals continue to smoke or have a history of smoking, contributing to the growing number of NSCLC cases.

Environmental factors, including exposure to air pollution and carcinogens like radon and asbestos, also play a role in the escalating incidence of NSCLC. Moreover, as the global population ages, the risk of developing NSCLC increases, as lung cancer is more common among older individuals. This demographic shift further intensifies the prevalence of NSCLC, particularly in developed nations with aging populations.

The consequences of the rising incidence of NSCLC are manifold and have a direct impact on the NSCLC market. First and foremost, the increased number of patients seeking diagnosis and treatment has fueled a growing demand for healthcare services, including advanced diagnostic tools like CT scans, PET scans, and genetic testing. This heightened demand has led to a corresponding increase in investments and innovations within the diagnostic sector of the NSCLC market.

Furthermore, the pharmaceutical industry has responded to this surge in NSCLC cases by intensifying research and development efforts. This has resulted in the emergence of more targeted therapies, immunotherapies, and combination treatment options, all of which are poised to offer improved outcomes for NSCLC patients. As the market expands to meet the needs of a larger patient population, it also attracts substantial investments, spurring competition and fostering the development of more effective and personalized treatment approaches.

Advancements in Diagnostic Technologies

Advancements in diagnostic technologies have played a pivotal role in boosting the Global Non-Small-Cell Lung Cancer (NSCLC) Market. Early and accurate diagnosis is a cornerstone of effective cancer management, and the rapid progress in diagnostic tools and techniques has significantly enhanced the ability to detect NSCLC at its earliest stages. One of the most notable advancements in NSCLC diagnostics is the refinement of imaging technologies. High-resolution Computed Tomography (CT) scans, Positron Emission Tomography (PET) scans, and magnetic resonance imaging (MRI) have become integral in the early detection and staging of NSCLC. These imaging modalities offer enhanced sensitivity and specificity, allowing healthcare professionals to visualize tumors with greater precision and assess their size and location, critical for treatment planning.

Genetic testing has also emerged as a transformative diagnostic tool in NSCLC. With the identification of specific genetic mutations and biomarkers associated with the disease, healthcare providers can now offer personalized treatment options. Tests for EGFR, ALK, ROS1, and other mutations help tailor therapy plans, maximizing the effectiveness of targeted therapies and minimizing side effects.

Liquid biopsies represent another groundbreaking development in NSCLC diagnostics. These minimally invasive tests analyze circulating tumor DNA (ctDNA) or tumor-derived RNA found in the bloodstream. Liquid biopsies can detect genetic mutations and biomarkers, providing a less invasive alternative to traditional tissue biopsies. This innovation not only expedites diagnosis but also allows for real-time monitoring of treatment response and the emergence of resistance, facilitating timely adjustments to therapy.

The integration of artificial intelligence (AI) and machine learning into diagnostic processes has further accelerated the pace of NSCLC diagnosis. AI-powered algorithms can analyze medical images and pathology slides with unmatched speed and accuracy, assisting radiologists and pathologists in detecting even subtle signs of NSCLC. This not only expedites diagnosis but also ensures consistency in interpretation across different healthcare settings.

Immunotherapy Breakthroughs

Immunotherapy breakthroughs have emerged as a significant catalyst in boosting the Global Non-Small-Cell Lung Cancer (NSCLC) Market. These innovative treatments have ushered in a new era of hope for NSCLC patients, offering the potential for extended survival and improved quality of life. At the forefront of immunotherapy in NSCLC are immune checkpoint inhibitors, particularly programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors. These drugs work by blocking the interaction between cancer cells and immune cells, essentially "releasing the brakes" on the immune system's ability to recognize and attack cancer cells. This approach has demonstrated remarkable success in clinical trials, with some patients experiencing durable responses even in advanced or metastatic stages of NSCLC.

Key immunotherapy breakthroughs in NSCLC include the approval of pembrolizumab, nivolumab, and atezolizumab, among others, which have become integral components of the treatment arsenal. These agents have not only provided patients with new hope but have also reshaped treatment paradigms, offering alternatives to traditional chemotherapy regimens. Immunotherapy's appeal lies in its potential for durable responses and fewer side effects compared to chemotherapy. Patients receiving immunotherapies often experience improved overall survival rates, and some have even achieved long-term remissions, transforming NSCLC from a dire diagnosis to a manageable chronic condition for some.

Furthermore, ongoing research and clinical trials are exploring combination therapies that combine immunotherapies with other treatment modalities like chemotherapy, targeted therapies, or radiation. These combinations aim to enhance response rates and overcome resistance mechanisms, further expanding the therapeutic options within the NSCLC market.

The success of immunotherapy in NSCLC is not only reshaping treatment approaches but also driving market growth. Pharmaceutical companies are investing heavily in research and development efforts to discover new immune checkpoint inhibitors and other immunotherapeutic agents. Additionally, the market is witnessing increased patient access to these therapies as more healthcare systems and insurers recognize their efficacy and include them in treatment guidelines.

Key Market Challenges

High Treatment Costs

Non-Small-Cell Lung Cancer (NSCLC) remains a formidable health challenge, with treatment costs emerging as a significant barrier to effective care. While medical advancements have expanded treatment options and improved outcomes for NSCLC patients, the exorbitant expenses associated with these therapies pose a daunting challenge that hinders progress in the Global NSCLC Market.

One of the primary drivers of high treatment costs in NSCLC is the development and availability of advanced therapies. Targeted therapies and immunotherapies have revolutionized the treatment landscape, offering promising results and improved survival rates. However, these groundbreaking treatments often come with a staggering price tag. The research and development investments required for the development of these therapies, along with the associated manufacturing and distribution costs, contribute to their high costs.

Furthermore, NSCLC treatment is typically a prolonged and multifaceted process, involving various modalities such as surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. These multiple interventions, coupled with the need for ongoing monitoring and follow-up care, further escalate the overall treatment expenses. Patients may face a continuous financial burden as they navigate the complexities of their treatment journey..

Limited Access to Innovative Therapies

The Global Non-Small-Cell Lung Cancer (NSCLC) Market has made significant strides in recent years with the development of innovative therapies, including targeted treatments and immunotherapies. However, a substantial challenge persists, hindering progress in the market: limited patient access to these cutting-edge therapies.

One of the primary factors contributing to limited access is the prohibitively high cost of innovative NSCLC treatments. Many of these therapies involve advanced technologies, intricate manufacturing processes, and specialized medications, all of which result in sky-high price tags. These costs often place an enormous financial burden on healthcare systems, insurers, and, most critically, patients themselves.

Healthcare disparities also play a significant role in limiting access to innovative NSCLC treatments. Access to state-of-the-art cancer care can vary dramatically depending on geographic location, economic status, and healthcare infrastructure. Patients in underserved regions or with limited financial means may find themselves at a significant disadvantage when it comes to accessing the latest therapies. Reimbursement policies and insurance coverage further compound the problem. Some insurance plans may not fully cover the cost of innovative NSCLC treatments, leaving patients to bear a substantial portion of the financial burden. Additionally, stringent eligibility criteria set by insurance companies can exclude certain patients from accessing these therapies, even when they may be medically appropriate.

Key Market Trends

Personalized Medicine and Targeted Therapies

Personalized Medicine and Targeted Therapies are playing a pivotal role in boosting the Global Non-Small-Cell Lung Cancer (NSCLC) Market. These innovative approaches represent a significant shift in the treatment paradigm for NSCLC patients, offering tailored and more effective interventions that are driving remarkable progress in the field.

Personalized medicine, often referred to as precision medicine, is at the forefront of NSCLC treatment trends. It involves tailoring medical decisions and treatments to the individual characteristics of each patient. In the context of NSCLC, this means identifying the specific genetic mutations and biomarkers associated with a patient's tumor to determine the most suitable course of treatment. This individualized approach has revolutionized NSCLC care, leading to more precise and effective therapies.

Targeted therapies, such as Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) inhibitors, exemplify the personalized medicine approach in NSCLC. These drugs are designed to target specific genetic alterations within cancer cells, thereby inhibiting their growth and proliferation. Patients with these genetic mutations can experience remarkable responses to targeted therapies, often with fewer side effects compared to traditional chemotherapy. The impact of personalized medicine and targeted therapies in NSCLC is profound. By matching treatment strategies to the unique genetic profile of each patient's tumor, healthcare providers can maximize the therapeutic benefit while minimizing unnecessary side effects. This approach not only improves treatment outcomes but also enhances the overall quality of life for NSCLC patients.

Moreover, ongoing research in the field is continually uncovering new genetic mutations and biomarkers, expanding the range of targeted therapies available. This provides a growing arsenal of treatment options for NSCLC patients, particularly those who may have previously faced limited choices.

Liquid Biopsies

Liquid biopsies have emerged as a transformative trend boosting the Global Non-Small-Cell Lung Cancer (NSCLC) Market. These innovative diagnostic tools are revolutionizing the way NSCLC is diagnosed and monitored, offering numerous advantages that are driving market growth. Liquid biopsies involve the analysis of circulating tumor DNA (ctDNA) or tumor-derived RNA found in a patient's bloodstream. Unlike traditional tissue biopsies, which require invasive procedures and may not always be feasible, liquid biopsies are minimally invasive and provide a convenient and repeatable method for detecting genetic mutations and biomarkers associated with NSCLC.

One of the key benefits of liquid biopsies is their ability to provide real-time information about the tumor's genetic profile and its response to treatment. This dynamic monitoring allows healthcare providers to make timely adjustments to treatment plans, optimizing therapy for individual patients. It also enables the early detection of resistance mechanisms that may develop during the course of treatment, enabling proactive intervention.

Liquid biopsies are particularly valuable in situations where tissue biopsies are challenging, such as when tumors are in difficult-to-reach locations or when patients are not surgical candidates. Additionally, they offer a less invasive alternative for patients who may be hesitant to undergo traditional biopsies due to their invasiveness and associated risks. The convenience and non-invasiveness of liquid biopsies also make them ideal for routine monitoring of NSCLC patients, allowing for more frequent assessments of disease progression and treatment response. This dynamic monitoring can lead to earlier intervention in cases of disease recurrence, potentially improving outcomes.

Furthermore, liquid biopsies are contributing to the early detection of NSCLC in at-risk populations, even before clinical symptoms manifest. This early detection can significantly improve the prognosis of NSCLC patients, as treatment is often more effective in the early stages of the disease.

Segmental Insights

Drug Class Insights

Based on the Drug Class, the Epidermal Growth Factor Receptor (EGFR) Inhibitors emerged as the dominant segment in the global market for Global Non-Small-Cell Lung Cancer Market in 2022. EGFR mutations are relatively common in NSCLC patients, particularly in specific demographic groups such as non-smokers and individuals of Asian descent. These mutations play a pivotal role in the development and progression of NSCLC. EGFR Inhibitors, such as gefitinib, erlotinib, and osimertinib, are specifically designed to target and inhibit the aberrant activity of EGFR in mutated forms. As a result, they are highly effective in a significant subset of NSCLC patients, creating a strong demand for these drugs.

Due to their proven effectiveness, EGFR Inhibitors have been incorporated into clinical practice guidelines for NSCLC management. Leading oncology organizations recommend EGFR testing as a routine part of NSCLC diagnosis, and EGFR Inhibitors are the first-line treatment of choice for patients with EGFR mutations.

Treatment Insights

Based on the Treatment, the Immunotherapy segment emerged as the dominant player in the global market for Global Non-Small-Cell Lung Cancer Market in 2022. Immunotherapy, specifically immune checkpoint inhibitors like PD-1 and PD-L1 inhibitors, has demonstrated the potential for durable responses in a subset of NSCLC patients. Some patients have experienced prolonged remissions and even long-term survival, which is less commonly observed with traditional chemotherapy. These positive outcomes have generated substantial demand for immunotherapy among both healthcare providers and patients.

The Targeted Therapy segment is anticipated to dominate a significant market share in the Non-Small Cell Lung Cancer (NSCLC) Market due to its clinical efficacy, precision medicine approach, minimal side effects .

Regional Insights

North America emerged as the dominant player in the global Non-Small-Cell Lung Cancer Market in 2022, holding the largest market share. North America boasts a highly developed healthcare infrastructure with a multitude of hospitals, clinics, and cancer centers equipped with state-of-the-art technology and skilled medical professionals. This infrastructure facilitates the diagnosis, treatment, and research efforts related to NSCLC.

North America has one of the highest incidences of lung cancer globally, with NSCLC being the most common subtype. The region's lifestyle factors, including a history of smoking and environmental exposures, contribute to the prevalence of NSCLC. This high disease burden drives the demand for NSCLC-related healthcare services and treatments.

Key Market Players

Eli Lilly and Company.

Sanofi SA

Novartis AG

F. Hoffmann-La Roche Ltd

Merck & Co., Inc.

Pfizer Inc.

AstraZeneca Plc

Boehringer Ingelheim Inc.

Bristol-Myers Squibb Company

Astellas Pharma

Report Scope:

In this report, the Global Non-Small-Cell Lung Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Non-Small-Cell Lung Cancer Market, By Type:

• Squamous Cell Carcinoma
• Large Cell Carcinoma
• Adenocarcinoma
• Others
• Global Non-Small-Cell Lung Cancer Market, By Drug Class
• Epidermal Growth Factor Receptor (EGFR) Inhibitors
• Anaplastic Lymphoma Kinase (ALK) Inhibitors
• ROS1 Inhibitors
• BRAF Inhibitors
• Others

Global Non-Small-Cell Lung Cancer Market, By Treatment:

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Global Non-Small-Cell Lung Cancer Market, By End-user
• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Global Non-Small-Cell Lung Cancer Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Non-Small-Cell Lung Cancer Market.

Available Customizations:

• Global Non-Small-Cell Lung Cancer Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Non-Small-Cell Lung Cancer Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Type (Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Others)
  • 4.2.2. By Drug Class (Epidermal Growth Factor Receptor (EGFR) Inhibitors, Anaplastic Lymphoma Kinase (ALK) Inhibitors, ROS1 Inhibitors, BRAF Inhibitors, Others)
  • 4.2.3. By Treatment (Chemotherapy, Targeted Therapy, Immunotherapy)
  • 4.2.4. By End-user (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 4.2.5. By Region
  • 4.2.6. By Company (2022)
• 4.3. Market Map
  • 4.3.1. By Type
  • 4.3.2. By Drug Class
  • 4.3.3. By Treatment
  • 4.3.4. By End-user
  • 4.3.5. By Region

5. Asia Pacific Non-Small-Cell Lung Cancer Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Drug Class
  • 5.2.3. By Treatment
  • 5.2.4. By End-user
  • 5.2.5. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Non-Small-Cell Lung Cancer Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Type
      • 5.3.1.2.2. By Drug Class
      • 5.3.1.2.3. By Treatment
      • 5.3.1.2.4. By End-user
  • 5.3.2. India Non-Small-Cell Lung Cancer Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Type
      • 5.3.2.2.2. By Drug Class
      • 5.3.2.2.3. By Treatment
      • 5.3.2.2.4. By End-user
  • 5.3.3. Australia Non-Small-Cell Lung Cancer Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Type
      • 5.3.3.2.2. By Drug Class
      • 5.3.3.2.3. By Treatment
      • 5.3.3.2.4. By End-user
  • 5.3.4. Japan Non-Small-Cell Lung Cancer Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Type
      • 5.3.4.2.2. By Drug Class
      • 5.3.4.2.3. By Treatment
      • 5.3.4.2.4. By End-user
  • 5.3.5. South Korea Non-Small-Cell Lung Cancer Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Type
      • 5.3.5.2.2. By Drug Class
      • 5.3.5.2.3. By Treatment
      • 5.3.5.2.4. By End-user

6. Europe Non-Small-Cell Lung Cancer Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Drug Class
  • 6.2.3. By Treatment
  • 6.2.4. By End-user
  • 6.2.5. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Non-Small-Cell Lung Cancer Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Drug Class
      • 6.3.1.2.3. By Treatment
      • 6.3.1.2.4. By End-user
  • 6.3.2. Germany Non-Small-Cell Lung Cancer Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Drug Class
      • 6.3.2.2.3. By Treatment
      • 6.3.2.2.4. By End-user
  • 6.3.3. Spain Non-Small-Cell Lung Cancer Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Drug Class
      • 6.3.3.2.3. By Treatment
      • 6.3.3.2.4. By End-user
  • 6.3.4. Italy Non-Small-Cell Lung Cancer Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Drug Class
      • 6.3.4.2.3. By Treatment
      • 6.3.4.2.4. By End-user
  • 6.3.5. United Kingdom Non-Small-Cell Lung Cancer Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Drug Class
      • 6.3.5.2.3. By Treatment
      • 6.3.5.2.4. By End-user

7. North America Non-Small-Cell Lung Cancer Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Drug Class
  • 7.2.3. By Treatment
  • 7.2.4. By End-user
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Non-Small-Cell Lung Cancer Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Drug Class
      • 7.3.1.2.3. By Treatment
      • 7.3.1.2.4. By End-user
  • 7.3.2. Mexico Non-Small-Cell Lung Cancer Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Drug Class
      • 7.3.2.2.3. By Treatment
      • 7.3.2.2.4. By End-user
  • 7.3.3. Canada Non-Small-Cell Lung Cancer Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Drug Class
      • 7.3.3.2.3. By Treatment
      • 7.3.3.2.4. By End-user

8. South America Non-Small-Cell Lung Cancer Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Drug Class
  • 8.2.3. By End-user
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Non-Small-Cell Lung Cancer Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Drug Class
      • 8.3.1.2.3. By Treatment
      • 8.3.1.2.4. By End-user
  • 8.3.2. Argentina Non-Small-Cell Lung Cancer Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Drug Class
      • 8.3.2.2.3. By Treatment
      • 8.3.2.2.4. By End-user
  • 8.3.3. Colombia Non-Small-Cell Lung Cancer Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Drug Class
      • 8.3.3.2.3. By Treatment
      • 8.3.3.2.4. By End-user

9. Middle East and Africa Non-Small-Cell Lung Cancer Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drug Type
  • 9.2.3. By Treatment
  • 9.2.4. By End-user
  • 9.2.5. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Non-Small-Cell Lung Cancer Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Drug Class
      • 9.3.1.2.3. By Treatment
      • 9.3.1.2.4. By End-user
  • 9.3.2. Saudi Arabia Non-Small-Cell Lung Cancer Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drug Type
      • 9.3.2.2.3. By Treatment
      • 9.3.2.2.4. By End-user
  • 9.3.3. UAE Non-Small-Cell Lung Cancer Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Drug Class
      • 9.3.3.2.3. By Treatment
      • 9.3.3.2.4. By End-user
  • 9.3.4. Egypt Non-Small-Cell Lung Cancer Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Type
      • 9.3.4.2.2. By Drug Class
      • 9.3.4.2.3. By Treatment
      • 9.3.4.2.4. By End-user

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Iron Deficiency Anemia: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Eli Lilly and Company
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Sanofi SA
• 14.3. Novartis AG
• 14.4. F. Hoffmann-La Roche Ltd
• 14.5. Merck & Co., Inc.
• 14.6. Pfizer Inc.
• 14.7. AstraZeneca Plc
• 14.8. Boehringer Ingelheim Inc.
• 14.9. Bristol-Myers Squibb Company
• 14.10. Astellas Pharma

15. Strategic Recommendations

16. About Us & Disclaimer